milrinone has been researched along with diltiazem in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ichikawa, H; Kawashima, Y; Koide, A; Komai, H; Nakashima, N; Ohashi, T; Shibata, T; Tanaka, K; Yamamoto, F; Yamamoto, H | 1 |
| Britton, LW; Ferraris, VA; Kiser, LM; Sim, MF; Wallace, AM; Weishaar, RE | 1 |
| Kiyota, T; Matsuda, F; Sadohara, T; Sugahara, K; Sugita, M; Terasaki, H | 1 |
| Adachi, H; Kakiki, M; Kishi, Y | 1 |
| Kirby, DS; Lobato, EB; Muehlschlegel, JD; Muehschlegel, JD; Sidi, A | 1 |
| Kaneko, H; Narita, Y; Oshima, H; Satake, M; Ueda, Y; Usui, A; Yagami, K; Yamawaki-Ogata, A | 1 |
| Barsys, V; Benetis, R; Garaliene, V; Giedraitis, S; Krauze, A | 1 |
1 review(s) available for milrinone and diltiazem
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
12 other study(ies) available for milrinone and diltiazem
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Harmful effects of inotropic agents on myocardial protection.
Topics: Animals; Body Temperature; Bucladesine; Calcium; Cardiotonic Agents; Creatine Kinase; Diltiazem; Hemodynamics; In Vitro Techniques; Isoproterenol; Male; Milrinone; Myocardial Reperfusion Injury; Pyridones; Rats; Rats, Inbred Strains; Ryanodine | 1991 |
Assessment of flosequinan's direct effect on human arterial, venous, and cardiac muscle: comparison with other classes of agents used to treat heart failure.
Topics: Captopril; Diltiazem; Heart Failure; Humans; In Vitro Techniques; Milrinone; Muscle Contraction; Muscle, Smooth, Vascular; Myocardial Contraction; Ouabain; Pyridones; Quinolines; Quinolones; Vasodilator Agents | 1994 |
Comparative effect of amrinone, aminophylline and diltiazem on rat airway smooth muscle.
Topics: Acetylcholine; Adrenergic beta-Agonists; Aminophylline; Amrinone; Animals; Bronchodilator Agents; Calcium Channel Blockers; Diltiazem; In Vitro Techniques; Isoproterenol; Milrinone; Muscle Relaxation; Muscle, Smooth; Rats; Rats, Wistar; Trachea | 2000 |
Effects of a phosphodiesterase 3 inhibitor, olprinone, on rhythmical change in tension of human gastroepiploic artery.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Amrinone; Calcium Channel Blockers; Cyclic Nucleotide Phosphodiesterases, Type 3; Diltiazem; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gastroepiploic Artery; Humans; Imidazoles; In Vitro Techniques; Milrinone; Muscle, Smooth, Vascular; Pyridones; RNA, Messenger; Time Factors; Vasodilation | 2005 |
Treating metabolic impairment and myocardial stunning with phosphodiesterase inhibitor type III, milrinone, administered prior to coronary artery occlusion in the presence of calcium channel blockade in pigs.
Topics: Analysis of Variance; Animals; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Cardiotonic Agents; Coronary Stenosis; Diltiazem; Disease Models, Animal; Heart Rate; Lactic Acid; Milrinone; Myocardial Contraction; Myocardial Reperfusion; Myocardial Stunning; Phosphodiesterase Inhibitors; Research Design; Swine; Time Factors; Vascular Resistance; Ventricular Function, Left; Ventricular Pressure | 2007 |
Prevention of arterial graft spasm in rats using a vasodilator-eluting biodegradable nano-scaled fibre.
Topics: Absorbable Implants; Animals; Arterial Occlusive Diseases; Calcium Channel Blockers; Constriction, Pathologic; Diltiazem; Disease Models, Animal; Drug Carriers; Femoral Artery; Male; Mice; Mice, Inbred C57BL; Milrinone; Nanofibers; Norepinephrine; Phosphodiesterase 3 Inhibitors; Polyglactin 910; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Time Factors; Vasoconstriction; Vasodilator Agents | 2013 |
The role of external Ca²⁺ in the action of Ca²⁺-channel agonists and antagonists on isolated human thoracic arteries.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Benzimidazoles; Calcium; Calcium Channel Agonists; Calcium Channel Blockers; Calcium Channels; Dihydropyridines; Diltiazem; Female; Humans; In Vitro Techniques; Isometric Contraction; Male; Middle Aged; Milrinone; Thoracic Arteries | 2014 |